Compare Amphastar Pharmaceuticals Inc (AMPH) vs Hormel Foods Corp (HRL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Hormel Foods Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Hormel Foods Corp trades at $24.52 (market cap $13.61B). The key difference: Hormel Foods Corp is far larger — about 16.5× Amphastar Pharmaceuticals Inc's market cap, and Hormel Foods Corp pays a 4.73% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | HRL | |
|---|---|---|
Market Cap | $826.08M | $13.61B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $30.51 |
52-Week Low | $16.87 | $19.74 |
Enterprise Value | $1.22B | $15.61B |
Dividend Yield | — | 4.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Hormel Foods (HRL) trades at $24.735, up 1.66% today, with a bearish technical signal but consistent earnings beats in recent quarters. The company maintains a 60-year dividend growth streak, paying $0.29 quarterly, while navigating margin pressures with a 3.82% net income margin. Recent news highlights strategic moves like the Ceratti Brazil sale to sharpen growth focus, though revenue trends remain flat near $12.1B.
Outlook is mixed: valuation appears reasonable (P/E 29.09, P/S 1.11) with analyst consensus at $26.00, but risks include volatile cash flows and competitive pressures. The stock offers income stability via dividends, yet investors face headwinds from inflation and sluggish profit growth, requiring patience for a turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
